



ATTORNEYS AT LAW

Robert Greene Sterne
George A. Goldstein
David E. Gammell
Mark A. Gammell
John M. Gammell
Tracy-Gene G. Gurkis
Michele A. Cirbusa
Michael J. Hickey
Robert E. Sokohl
Eric K. Steffie
Mark A. Tice
John M. Covert
Robert C. Milazzo
Donald J. Fauthstone
Thomas J. Kline
Michael V. Messenger
Judith L. Kim
Jeffrey Z. Helvey
Eldora L. Ellison

Peter A. Jackman
Brian A. Janczuk
Matt For Evans
Vincent L. Capuano
Elizabeth J. Hawes
Michael J. Hickey
Kevin W. McCabe
Gene J. Penny
Edward J. Yerl
Graet L. Hwang
Vigil L. Beaton
Theodore A. Wood
Joseph J. Kline
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LaUanne M. DeSantis

Ann E. Summerfield
Helene C. Carlson
Caroline M. Hernandez
Timothy A. Doyle
Gaby L. Longsworth
Lori A. Gordon
Laura M. Kline
Bryan S. Waite
Bashir M.S. Ali
Sharmila M. Carroll
Anilur K. Khalil
Michelle K. Holoubek
Marsha A. Rose
Scott A. Shuler
Lei Zhou
W. Blake Cobenzl
James J. Hall
John L. Hasan

Mark W. Rygal
Michael R. Malek*
Jeffrey A. Kline
Daryl A. Smith
Doris A. Sorkin
Ulrike Winkler Jeni
Paul A. Calvo
Robert J. Karpman
C. Matthew Rizer**
Shameek Ghose
Randall J. Baldwin
Daniel J. Neary
Recipient Patent Agents -
Karen B. Markowicz
Matthew J. Dowd
Mita Mahurkar
Scott M. Woodhouse
Peter A. Scarama

Jeffrey K. Mills
Danielle L. Letting
Caren Braverman
Steven C. Oopenheimer
Aaron S. Lukas
Gaurav Athana

Of Counsel

Edward J. Kessler
Kenneth C. Bass III
Marvin C. Gaffne
Christopher F. Wrist
*Admitted only in Maryland
**Admitted only in Virginia
**Provisionally admitted to
Federal Agencies

October 22, 2007

WRITER'S DIRECT NUMBER:

(202) 772-8679

INTERNET ADDRESS:

TSHEA@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1636

Re: U.S. Utility Patent Application
Application No. 10/633,697; Filed: August 5, 2003
For: Glycosylation Engineering of Antibodies for Improving Antibody-
Dependent Cellular Cytotoxicity
Inventors: UMAÑA *et al.*
Our Ref: 1975.0010005/TJS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Continued Examination (RCE) Transmittal;
2. Amendment and Reply Under 37 C.F.R. §1.111 and §1.114;
3. Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending "Reference" Application;
4. Terminal Disclaimer to Obviate a Double Patenting Rejection Over a "Prior" Patent;
5. Statement Under 37 CFR §3.73(b);
6. Power of Attorney to Prosecute Applications;
7. Second Supplemental Information Disclosure Statement;
8. Form PTO/SB/08A (1 sheet) listing 10 documents (AA2 to AE2 and AL2 to AP2);
9. Form PTO/SB/08B (3 sheets) listing 23 documents (AR55 to AS62); and
10. Copies of cited documents (AL2-AP2 and AR55-AS62).

Commissioner for Patents
October 22, 2007
Page 2

11. Online Credit Card Payment Authorization in the amount of \$1,250.00 to cover:

\$810.00 Fee for Requested for Continued Examination (RCE);

\$260.00 Fees for two Terminal Disclaimers; and

\$180.00 Fee for Second Supplemental Information Disclosure Statement.


The above-listed documents are being filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Fee payment is provided through online credit card payment. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Timothy J. Shea, Jr.
Attorney for Applicants
Registration No. 41,306

TJS/lrd
Enclosures

735126_1.DOC